Who owns Sarepta Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SRPT from SEC Form 13F filings across 305 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 305 institutions disclosed 105.1M shares of Sarepta Therapeutics, Inc. worth $1.92B — about 99.2% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
305
13F holders
$1.92B
value, 2026 filers
99.2%
of shares outstanding (105.1M sh)
40
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of SRPT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 18.8M | $342.1M | 0.0% | 17.7% | -1.2% |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8.7M | $158.5M | 0.0% | 8.2% | +3.8% |
| 3 | STATE STREET CORP | 7.4M | $135.1M | 0.0% | 7% | -16.9% |
| 4 | FIRST TRUST ADVISORS LP | 4.9M | $89.7M | 0.1% | 4.6% | +12.8% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $83.8M | 0.0% | 4.3% | +0.2% |
| 6 | TWO SIGMA INVESTMENTS, LP | 4.5M | $81.6M | 0.1% | 4.2% | -2.7% |
| 7 | GOLDMAN SACHS GROUP INC | 3.3M | $59.7M | 0.0% | 3.1% | +60.4% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.7M | $49.0M | 0.0% | 2.5% | -3.1% |
| 9 | Balyasny Asset Management L.P. | 2.5M | $44.7M | 0.1% | 2.3% | +1510.6% |
| 10 | Erste Asset Management GmbH | 2.3M | $42.1M | 0.3% | 2.1% | -11.7% |
| 11 | BANK OF AMERICA CORP /DE/ | 2.1M | $37.9M | 0.0% | 2% | +1.3% |
| 12 | MARSHALL WACE, LLP | 2.0M | $36.7M | 0.0% | 1.9% | -8.6% |
| 13 | Casdin Capital, LLC | 1.8M | $33.2M | 1.4% | 1.7% | +287.2% |
| 14 | FEDERATED HERMES, INC. | 1.6M | $28.8M | 0.0% | 1.5% | -0.6% |
| 15 | MORGAN STANLEY | 1.4M | $25.1M | 0.0% | 1.3% | -37.5% |
| 16 | UBS Group AG | 1.3M | $23.3M | 0.0% | 1.2% | -21.3% |
| 17 | NORTHERN TRUST CORP | 1.2M | $21.5M | 0.0% | 1.1% | -2.6% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1M | $20.2M | 0.0% | 1% | +13.1% |
| 19 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $20.0M | 0.0% | 1% | +56.1% |
| 20 | Invesco Ltd. | 1.1M | $19.8M | 0.0% | 1% | +20.2% |
| 21 | Frazier Life Sciences Management, L.P.NEW | 1.1M | $19.5M | 0.5% | 1% | new |
| 22 | Logos Global Management LPNEW | 1.0M | $18.2M | 1.0% | 0.9% | new |
| 23 | ADAR1 Capital Management, LLC | 952,063 | $17.3M | 0.8% | 0.9% | +30.3% |
| 24 | Nuveen, LLC | 898,648 | $16.4M | 0.0% | 0.8% | +136.9% |
| 25 | Point72 Asset Management, L.P. | 805,759 | $14.7M | 0.0% | 0.8% | +57.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.